ICICI Prudential Mutual Fund increased its shareholding in PI Industries to 7.16%, buying nearly 4.4 lakh shares, indicating a positive outlook towards the company's recovery potential. Despite a significant QoQ profit drop and YoY revenue decline in FY26, PI Industries' stock appreciated by 3% on BSE, closing at ₹2,820.10.

Nuvama has kept its neutral stance on PI Industries, reducing the price target to INR 3,166 from previous INR 3,645, indicating a slightly revised outlook for the company's performance.

PI Industries' earnings disappoint, causing a decline in its shares, while Mankind Pharma experiences growth due to strong earnings. Meanwhile, Godawari Power, Karnataka Bank, and Dredging Corp have all seen an increase in their shares, following robust results.

PI Industries experiences a significant drop following Q4 results that fell short of expectations, causing analysts to label the company as today's 'Performance Pitfall.'

Despite Q4 earnings missing expectations for EBITDA and PAT, Jefferies remains optimistic about PI Industries, maintaining a 'Buy' rating with a revised target of ₹3575. The bullish outlook is fueled by projected growth from new molecules and a predicted 12% annual increase in profit after tax (PAT) from FY26 to FY28, anticipating recovery by FY27.

DAM Capital maintains a sell recommendation for PI Industries, predicting a target price of ₹2556. This decision is based on challenges in the Agchem sector and weak domestic demand, leading to reduced EPS projections for FY27/FY28 due to slow growth. Additionally, the company anticipates margin pressure due to increased costs and R&D expenditure.

HSBC maintains its neutral stance on PI Industries, setting a price target at ₹3000, despite weak Q4FY26 results attributed to challenges in the agribusiness sector and rising overhead costs. The bank's assessment suggests earnings may be impacted by uncertainties in the core business and slow growth of new initiatives.

Morgan Stanley maintains its bullish stance on PI Industries, setting a target price of INR 3,883. Investors may find this stock appealing due to the firm's optimistic outlook.

Motilal Oswal remains optimistic about PI Industries, suggesting a buy with a target of Rs 3,500, despite the company's weak Q4 performance. Despite a 15% decrease in CSM revenue year-over-year, growth is anticipated in FY27 due to new molecules and a robust order book in the pharma sector.

PI Industries aims to increase its market share by focusing on expanding volume rather than margins, setting a goal of generating INR 100 crore in revenue from electronic chemicals within the next four to five years.

PI Industries anticipates growth in the upcoming fiscal year, fueled by new product launches such as Pioxaniliprole. The company's focus on pharmaceutical and electronics sectors will be instrumental to its growth strategy.

PI Industries experienced an approximately 8% decline in share price due to missing targets in their Q4 results, as reported by ET NOW.

PI Industries announced a final dividend of ₹10 per share for FY26, making the total dividend ₹15 per share for the year. Notably, Rajnish Sarna stepped down as Joint Managing Director, and Arvind Singhal retired, with new directors joining the board.

PI Industries announced a final dividend of INR 10 per share, offering a return to shareholders ahead of the new year.

Mankind Pharmaceuticals demonstrates robust operational success, maintaining a recommended price range of 2528-2575. On the other hand, PI Industries continues to underperform, prompting a downward revision of the target price to 3010 due to persistent weak results.

PI Industries experiences a 7% dip, making it the leading loss in the futures market. The significant decline might be attributed to a weak outlook, mounting margin pressure, or a major catalyst causing concern.

PI Industries and PTC India experience an 8% and 7% dip in their stock prices respectively, following the release of their Q4 results. On a positive note, BLS International Services reports a 7% increase in its stock price after announcing Q4 earnings.

PI Industries reported a significant drop in Q4 net profit by 39%, largely due to a 26% decrease in EBITDA and a 12% decline in revenue, amounting to ₹1,565 crore. The company has expressed caution about its FY27 outlook, attributing it to increasing input costs.

PI Industries experiences a 12% decrease in quarterly revenue for Q4FY26 compared to the previous year, with profit margins dropping by 400 basis points to 21.5%.

PI Industries experienced a 12% decline in Q4 revenue compared to the previous year, with EBITDA also decreasing by 26%. Despite this drop in overall revenue for FY26 (down 16%), the pharmaceutical sector saw growth of 23%. The company has announced a dividend of Rs 15 per share.

PI Industries reports a significant 28% decline in Q4 EBITDA compared to the previous year, dropping from ₹4.6B to ₹3.3B. The company's earnings margin also shrunk from 25.6% to 21.6%.

Today saw a dip in small and mid-cap stocks, with companies such as Hindustan Copper, Devyani, and PI Industries experiencing drops of around 7%. This downward trend may signal investor uncertainty or selling pressure in these sectors.

PI Industries experiences a dip, with analyst Janhavi Ladda examining the company's recent performance. Her assessment provides insights into potential factors influencing the drop.

Anticipation builds for PI Industries' Q4 financial results, as predicted by AwaazEarnings. Investors eagerly await the company's latest performance update.

PI Industries will announce their financial results for the fiscal year 2026 and potentially declare a dividend at a board meeting scheduled for May 19, 2026. From April 1 to May 21, 2026, trading in the company's securities is suspended, with trading resuming on May 22.